Study guide
DIC, VTE, Bleeding, and Thrombotic Emergencies
OCN Oncology Certified Nurse Study Guide Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: OCN Exam Orientation and Official Source Control
Official Sources and Credential Purpose Eligibility, Application, and Fees Exam Format, Scoring, Blueprint, and Generic Drugs PSI Scheduling, ATT, Test Day, and Results Blueprint-Based Study Plan and Readiness
2 Chapter 2: Care Continuum, Prevention, Survivorship, and End-of-Life Care
Health Promotion, Risk Reduction, and Epidemiology Screening, Early Detection, and High-Risk Referrals Navigation, Coordination, and Care Continuity Palliative Care, Advance Care Planning, and Goals Survivorship, Rehabilitation, Recurrence, and Late Effects Sexuality, Family Support, Discrimination, and Social Needs End-of-Life Care, Hospice, Bereavement, and Comfort Measures
3 Chapter 3: Oncology Science and Site-Specific Cancer Assessment
Carcinogenesis, Immunology, and Cancer Biology Genomic, Genetic Testing, and Biomarker Literacy Clinical Trials, Research Protocols, and Informed Participation Diagnostic Workup, Biopsy, Imaging, and Pathology Basics Staging, Grading, Prognosis, and Performance Status Common Cancer Patterns and Metastatic Sites Oncology Assessment, Data Clustering, and Escalation
4 Chapter 4: Professional Oncology Nursing Practice, Safety, and Standards
Scope, Standards, Nursing Process, and Documentation Collaboration, Communication, and Interprofessional Practice Safe Handling, PPE, Occupational Health, and Exposure Response Culturally Congruent Care, Advocacy, and Ethics Self-Care, Compassion Fatigue, Burnout, and Professional Development
5 Chapter 5: Treatment Modalities I - Surgery, Radiation, Transplant, Localized and Oral Therapy
Surgery and Procedural Oncology Nursing Care Radiation Therapy Principles, Toxicities, and Teaching Blood and Marrow Transplant Foundations Localized Therapy: Intrathecal, Intravesical, and Regional Care Oral Oncology Therapy Adherence, Safety, and Education Treatment Sequencing, Response Monitoring, and Care Coordination Modality-Specific Patient Teaching and Documentation
6 Chapter 6: Treatment Modalities II - Systemic Therapy, Immunotherapy, and Targeted Agents
Chemotherapy Foundations and Infusion Safety Biotherapy, Immunotherapy, and Immune-Related Adverse Events Targeted Therapy, Immune Cell, and Bispecific Antibody Basics Hormonal Therapy and Endocrine Cancer Treatment Considerations Vascular Access, Infusion Monitoring, and Extravasation Prevention Systemic Therapy Patient Education and Home Safety Therapy Response, Adherence, and Toxicity Escalation
7 Chapter 7: Symptom Management and Supportive Care
Symptom Assessment, Toxicity Grading, and Prioritization Hematologic, Immunologic, and Infection Supportive Care GI, GU, Nutrition, and Hydration Supportive Care Integumentary, Ostomy, Lymphedema, and Wound Care Respiratory, Cardiovascular, Neurologic, and Musculoskeletal Symptoms Pain Management, Pharmacologic, and Integrative Care Vascular Access Device Care and Supportive Care Coordination
8 Chapter 8: Oncologic Emergencies and Rapid Escalation
Sepsis, SIRS, Neutropenic Infection, and Shock Tumor Lysis, Hypercalcemia, SIADH, and Metabolic Emergencies Hypersensitivity, Anaphylaxis, and Infusion Reactions Spinal Cord Compression, SVC Syndrome, Increased ICP, and Obstructions DIC, VTE, Bleeding, and Thrombotic Emergencies Pneumonitis, Extravasation, and Local Therapy Emergencies Immune-Related Emergencies, CRS, ICANS, and Urgent Triage
9 Chapter 9: Psychosocial Dimensions of Oncology Care
Distress Screening, Emotional Response, and Crisis Care Cultural, Spiritual, Religious, and Language-Responsive Care Family, Caregiver Support, and Shared Decision-Making Sexuality, Fertility, Gender, and Body Image Concerns Learning Barriers, Health Literacy, and Patient Education Financial Toxicity, Support Systems, and Resource Referrals
10 Chapter 10: Mixed OCN Case Labs
New Diagnosis Navigation and Treatment Planning Case Lab Chemotherapy Infusion Reaction and Extravasation Case Lab Immunotherapy Toxicities and CRS ICANS Case Lab Radiation Surgery and Localized Therapy Case Lab Symptom Management Neutropenia Pain and Nutrition Case Lab Oncologic Emergency TLS SVC Cord Compression Case Lab Survivorship Palliative Psychosocial and Discharge Case Lab
11 Chapter 11: Final Review, High-Yield Tables, and OCN Exam-Day Readiness
Blueprint Quick Reference and Domain Triage High-Yield Oncology Safety and Emergency Tables Generic Drug Stems, Labs, and Supportive Care Patterns Final Week Practice Plan, Error Log, and Stamina Final 48 Hours, PSI Test Day, and Retake Planning
DIC, VTE, Bleeding, and Thrombotic Emergencies
Key Takeaways Explain This Topic AI
Disseminated intravascular coagulation (DIC) shows falling platelets and fibrinogen with prolonged PT and aPTT and a markedly elevated D-dimer; it classically accompanies sepsis and acute promyelocytic leukemia.
Cancer-associated thrombosis is common and often treated with low-molecular-weight heparin or a direct oral anticoagulant rather than warfarin.
Institute bleeding precautions when the platelet count falls below 50,000/mcL, and spontaneous bleeding risk rises sharply below 10,000 to 20,000/mcL, the common platelet transfusion trigger.
Never massage a painful, swollen limb suspected of deep vein thrombosis, and escalate sudden dyspnea with pleuritic chest pain as possible pulmonary embolism.
The RN should not independently hold or restart anticoagulants but must make the competing bleeding and clotting risks visible to the team quickly.
Last updated: June 2026
DIC, VTE, Bleeding, and Thrombotic Emergencies
Cancer creates a prothrombotic state , yet many treatments simultaneously raise bleeding risk. Tumor cells, inflammatory cytokines, immobility, surgery, central venous catheters, hormonal and antiangiogenic agents (e.g., bevacizumab), thrombocytopenia, liver dysfunction, and infection all contribute. The RN's framing question is: is this patient bleeding, clotting, or both at once?
Disseminated Intravascular Coagulation
Disseminated intravascular coagulation (DIC) is systemic activation of coagulation that consumes platelets and clotting factors while forming microvascular thrombi - paradoxically producing both bleeding and clotting. It accompanies sepsis, acute promyelocytic leukemia (APL), advanced malignancy, massive tissue injury, and transfusion reactions . Findings include petechiae, ecchymoses, mucosal bleeding, hematuria, melena, oozing from IV and line sites, dyspnea, renal dysfunction, confusion, and limb ischemia.
- Lab Direction in DIC Meaning
- Platelets Falling Consumption
- PT and aPTT Prolonged Factor depletion
- Fibrinogen Low Consumption; bleeding risk
- D-dimer Markedly elevated Active fibrin breakdown
- Schistocytes Present on smear Microangiopathic hemolysis
Nursing actions: frequent vitals, head-to-toe bleeding assessment, neuro checks, intake and output, line-site checks, and rapid reporting of abnormal labs or active bleeding. Treatment targets the underlying cause and replaces components - fresh frozen plasma for factors, cryoprecipitate for fibrinogen, and platelets - with heparin only in selected thrombosis-predominant cases. Avoid unnecessary venipunctures and rectal procedures.
Venous Thromboembolism
Venous thromboembolism (VTE) - deep vein thrombosis (DVT) and pulmonary embolism (PE) - is one of the most common and lethal complications of cancer. DVT presents with unilateral leg swelling, pain, warmth, erythema, or catheter-associated arm swelling. PE presents with sudden dyspnea, pleuritic chest pain, tachycardia, hypoxia, cough, hemoptysis, syncope, or shock.
Do not massage a painful, swollen limb - you can dislodge a clot. Assess pulses, color, temperature, edema, oxygen saturation, and chest symptoms, and escalate immediately for suspected PE. A high-yield treatment point: cancer-associated thrombosis is preferentially anticoagulated with low-molecular-weight heparin (e.g., enoxaparin) or a direct oral anticoagulant (DOAC) rather than warfarin , because warfarin is less effective and harder to control around chemotherapy, nausea, and procedures.
Bleeding Emergencies and Platelet Thresholds
Bleeding risk climbs with thrombocytopenia, anticoagulants, liver dysfunction, DIC, and mucositis. Memorize the platelet thresholds:
- Platelet count (/mcL) Implication
- Below 50,000 Initiate bleeding precautions; bleeding with trauma or surgery
- 10,000 to 20,000 Spontaneous bleeding risk; common prophylactic transfusion trigger
- Below 10,000 High risk of spontaneous intracranial hemorrhage
Bleeding precautions: avoid intramuscular injections, use a soft toothbrush and electric razor, no rectal suppositories or enemas, apply pressure to puncture sites, and avoid aspirin and NSAIDs. Urgent signs include hematemesis, melena, large-volume bleeding, severe headache, focal neurologic deficit, hypotension, or syncope - intracranial hemorrhage can present as headache, vomiting, seizure, or mental status change.
Balancing Bleeding and Clotting Risk
The defining oncology challenge is the patient who must be anticoagulated for a clot yet also has thrombocytopenia, brain metastases, recent surgery, or active bleeding. The RN should not independently hold or restart anticoagulants outside policy, but must make the competing risk visible immediately: report the platelet count, hemoglobin trend, renal function (which affects enoxaparin dosing), any active bleeding, falls or head strikes, planned procedures, and the current anticoagulant dose and last administration time. For suspected stroke, limb ischemia, massive PE, or intracranial hemorrhage, activate emergency pathways at once.
Anticoagulant and Bleeding Education
Teach patients why anticoagulation matters, how to take it, what to do for a missed dose, and which signs demand urgent care: black or tarry stools, vomiting blood, severe headache, a fall with head strike, unusual bruising, persistent nosebleeds, pink or red urine, heavy vaginal bleeding, chest pain, dyspnea, or unilateral limb swelling. Reinforce both sides of the balance - do not skip anticoagulants without direction, and do not ignore bleeding or head trauma .
Prevention includes mobility as tolerated, hydration when appropriate, and meticulous central-line care, while remembering that the cancer itself keeps clot risk elevated even during active treatment.
Reversal, Transfusion Thresholds, and Reassessment
Know the basics of anticoagulant reversal because the nurse must anticipate orders during major bleeding: protamine sulfate reverses heparin and partially reverses low-molecular-weight heparin, vitamin K plus prothrombin complex concentrate reverses warfarin, idarucizumab reverses dabigatran, and andexanet alfa reverses the factor Xa inhibitors apixaban and rivaroxaban. For active or major bleeding, also anticipate red-cell transfusion guided by hemoglobin and symptoms and platelet transfusion when the count is low.
Remember that an isolated thrombocytopenia does not always mean DIC - it can reflect marrow suppression, immune thrombocytopenia, or heparin-induced thrombocytopenia, which paradoxically causes clotting and requires stopping all heparin.
Reassessment is continuous in these patients. After a fluid bolus or transfusion, recheck blood pressure, heart rate, mental status, and any bleeding site; a transient improvement that fades signals ongoing blood loss. Track the hemoglobin and platelet trends, not single values, and report a rapidly falling hemoglobin even if the absolute number still looks acceptable. The recurring OCN theme is that oncology coagulopathy is a moving target - the same patient can shift from a clotting emergency to a bleeding emergency within a single shift, so the nurse keeps both risks in view and surfaces the changing picture to the team promptly.